FACSAria Flow Cytometer

FACSAria流式细胞仪

基本信息

  • 批准号:
    7212960
  • 负责人:
  • 金额:
    $ 34.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-02-15 至 2008-02-14
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Over the last 2 decades, flow cytometry has evolved into a technology that provides for the detection of molecules on the cell surface, the monitoring of cellular processes from gene regulation to protein-protein interaction, and the rapid isolation of cells, from bacterial to mammalian, that display desirable phenotypes. Until the last three years, fluorescence-activated cell sorters capable of multicolor detection and high-speed cell isolation, such as our FACSVantage (acquired in 1994 with NIH support), are large intricate instruments that require special laboratory facilities and high cost maintenance. The FACSAria is a new generation bench-top cell sorter with significant advances in optics, detection sensitivity, fluidics, acquisition rate, and sort capability. It is a timely and vital replacement for our FACSVantage. The arrival of two major users, and a recently established Department of Medical Parasitology, bring unprecedented demands on flow cytometry utilization at NYUSM. The FACSAria will provide high speed cell isolation, exceptional pathogen containment, additional color detection, maximal operator productivity, and low maintenance costs. There is no comparable instrument at NYUSM. Under the auspices of the CFAR Flow Cytometry Core directed by Dr. Doris Tse, it will be a shared resource available to all scientists at NYUSM, its affiliates, and neighboring research institutions. Usage will be monitored by the CFAR executive committee with an internal and external advisory board. Operator salary, consumable supplies, and maintenance fees will be covered in part by an NIH award (P30 AI27742), and charged in part to individual grants under an ongoing user-chargeback system. Dr. Tse, who has extensive hands-on flow cytometry experience, will promote instrument utilization and innovative research applications, validate data interpretation, supervise operators, and mandate quality controls. This instrument will be used to study human cells and animal cells infected with pathogens. These studies will advance our understanding of the etiology and pathology underlying many diseases, including HIV, TB, asthma, sepsis, malaria, hepatitis, sleep apnea, and environmental toxicant exposure. This information will potentiate the development or improvement of medical procedures towards their prevention and treatment.
描述(由申请人提供):在过去的20年中,流式细胞术已经发展成为一种技术,用于检测细胞表面上的分子,监测从基因调控到蛋白质-蛋白质相互作用的细胞过程,以及快速分离显示所需表型的细胞(从细菌到哺乳动物)。直到最近三年,荧光激活的细胞分选仪能够快速检测和高速细胞分离,如我们的FACSVantage(1994年在NIH的支持下收购),是需要特殊实验室设施和高成本维护的大型复杂仪器。FACSAria是新一代台式细胞分选仪,在光学、检测灵敏度、射流、采集速率和分选能力方面都有显著进步。它是我们FACSVantage的及时和重要替代品。两个主要用户的到来,以及最近成立的医学寄生虫学系,对纽约大学的流式细胞术利用率提出了前所未有的要求。FACSAria将提供高速细胞分离、特殊的病原体遏制、额外的颜色检测、最大的操作者生产力和低维护成本。纽约州立大学没有类似的文书。在Doris Tse博士指导的CFAR流式细胞术核心的主持下,它将成为NYUSM,其附属机构和邻近研究机构的所有科学家的共享资源。使用情况将由CFAR执行委员会与内部和外部咨询委员会监测。操作员工资、耗材和维护费将部分由NIH奖励(P30 AI 27742)支付,部分由正在进行的用户退款系统下的个人赠款支付。Tse博士拥有丰富的流式细胞术实践经验,将促进仪器利用和创新研究应用,验证数据解释,监督操作员并进行质量控制。该仪器将用于研究感染病原体的人类细胞和动物细胞。这些研究将促进我们对许多疾病的病因学和病理学的理解,包括艾滋病毒、结核病、哮喘、败血症、疟疾、肝炎、睡眠呼吸暂停和环境毒物暴露。这些信息将有助于制定或改进预防和治疗这些疾病的医疗程序。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DORIS B TSE其他文献

DORIS B TSE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DORIS B TSE', 18)}}的其他基金

FLOW CYTOMETRY CORE
流式细胞术核心
  • 批准号:
    6936128
  • 财政年份:
    2005
  • 资助金额:
    $ 34.4万
  • 项目类别:
CORE--FLOW CYTOMETRY FACILITY
核心——流式细胞仪
  • 批准号:
    6470585
  • 财政年份:
    2001
  • 资助金额:
    $ 34.4万
  • 项目类别:
ACTIVATION AND SENESCENCE OF HELPER T LYMPHOCYTES
辅助 T 淋巴细胞的激活和衰老
  • 批准号:
    2887947
  • 财政年份:
    1998
  • 资助金额:
    $ 34.4万
  • 项目类别:
ACTIVATION AND SENESCENCE OF HELPER T LYMPHOCYTES
辅助 T 淋巴细胞的激活和衰老
  • 批准号:
    2801936
  • 财政年份:
    1998
  • 资助金额:
    $ 34.4万
  • 项目类别:
ACTIVATION AND SENESCENCE OF HELPER T LYMPHOCYTES
辅助 T 淋巴细胞的激活和衰老
  • 批准号:
    6436128
  • 财政年份:
    1998
  • 资助金额:
    $ 34.4万
  • 项目类别:
REGENERATION OF CD4 LYMPHOCYTES
CD4 淋巴细胞的再生
  • 批准号:
    2673122
  • 财政年份:
    1997
  • 资助金额:
    $ 34.4万
  • 项目类别:
REGENERATION OF CD4 LYMPHOCYTES
CD4 淋巴细胞的再生
  • 批准号:
    2431624
  • 财政年份:
    1997
  • 资助金额:
    $ 34.4万
  • 项目类别:
FLOW CYTOMETRY CORE
流式细胞术核心
  • 批准号:
    7480324
  • 财政年份:
  • 资助金额:
    $ 34.4万
  • 项目类别:
FLOW CYTOMETRY CORE
流式细胞术核心
  • 批准号:
    7310116
  • 财政年份:
  • 资助金额:
    $ 34.4万
  • 项目类别:
FLOW CYTOMETRY CORE
流式细胞术核心
  • 批准号:
    7671466
  • 财政年份:
  • 资助金额:
    $ 34.4万
  • 项目类别:

相似海外基金

Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
  • 批准号:
    2901112
  • 财政年份:
    2024
  • 资助金额:
    $ 34.4万
  • 项目类别:
    Studentship
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
  • 批准号:
    485504
  • 财政年份:
    2023
  • 资助金额:
    $ 34.4万
  • 项目类别:
    Salary Programs
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
  • 批准号:
    495593
  • 财政年份:
    2023
  • 资助金额:
    $ 34.4万
  • 项目类别:
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
  • 批准号:
    485322
  • 财政年份:
    2023
  • 资助金额:
    $ 34.4万
  • 项目类别:
    Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
  • 批准号:
    493135
  • 财政年份:
    2023
  • 资助金额:
    $ 34.4万
  • 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
  • 批准号:
    493526
  • 财政年份:
    2023
  • 资助金额:
    $ 34.4万
  • 项目类别:
    Operating Grants
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
  • 批准号:
    10659658
  • 财政年份:
    2023
  • 资助金额:
    $ 34.4万
  • 项目类别:
Treating Maternal Depression in an Urban Community-Based Pediatric Asthma Clinic: Targeting Maternal Mood, Child Asthma Outcomes, and Health Disparities
在城市社区小儿哮喘诊所治疗孕产妇抑郁症:针对孕产妇情绪、儿童哮喘结果和健康差异
  • 批准号:
    10723233
  • 财政年份:
    2023
  • 资助金额:
    $ 34.4万
  • 项目类别:
Improving Prediction of Asthma-related Outcomes with Genetic Ancestry-informed Lung Function Equations
利用遗传祖先信息的肺功能方程改善哮喘相关结果的预测
  • 批准号:
    10723861
  • 财政年份:
    2023
  • 资助金额:
    $ 34.4万
  • 项目类别:
Prenatal Fatty Acid Supplementation and Early Childhood Asthma and Atopy in Black American Families
美国黑人家庭产前脂肪酸补充剂与儿童早期哮喘和特应性
  • 批准号:
    10586398
  • 财政年份:
    2023
  • 资助金额:
    $ 34.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了